Last reviewed · How we verify
NCT03217110
Cerebellar Stimulation and Cognitive Control
NA trial testing Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia in 200 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | Krystal Parker, PhD |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 200 |
| Start date | 30 November 2017 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
- Bipolar Disorder — all drugs for Bipolar Disorder →
- Depression — all drugs for Depression →
Sponsor
Krystal Parker, PhD
Who can join
Adults 18 to 90, any sex, with Schizophrenia or Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neurocognitive functioning in bipolar disorder: What we know and what we don't.
Keramatian K, Torres IJ, Yatham LN. · · 2021 · cited 48× · PMID 35860174 · DOI 10.1080/19585969.2022.2042164 -
Recent advancements in noninvasive brain modulation for individuals with autism spectrum disorder.
Griff JR, Langlie J, Bencie NB, Cromar ZJ, et al · · 2023 · cited 13× · PMID 36453393 · DOI 10.4103/1673-5374.360163
Verify or expand the search:
- PubMed search for NCT03217110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Repetitive Transcranial Magnetic Stimulation (rTMS)
Trials testing the same drug.
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT06953596 — Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder · NA · not yet recruiting
- NCT06991062 — Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHAS · NA · recruiting
- NCT05426967 — rTMS for Military TBI-related Depression · NA · recruiting
- NCT06639594 — Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study · Phase 1 · recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03217110 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Krystal Parker, PhD
- Last refreshed: 19 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03217110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing